Protagonist reports Q4 net loss $0.69/shr, cash $237M; positive Ph2b JNJ-2113 and rusfertide REVIVE data

Protagonist Therapeutics, Inc

Net loss per share Q4 2022: $0.69 ($34.2M) vs $0.77 ($36.9M) in Q4 2021; full year 2022 net loss $127.4M.
Cash, cash equivalents and marketable securities $237.4M at Dec 31, 2022; expected to fund operations through end of 2024.
Phase 2b FRONTIER 1 study of JNJ-2113 in psoriasis met primary endpoint: statistically significant PASI-75 at Week 16 across all doses, well tolerated.
Phase 2 REVIVE study of rusfertide in polycythemia vera met primary endpoint: proportion of responders on rusfertide vs placebo p=0.0003; 92.3% phlebotomy-free.
License revenue from Janssen collaboration declined to zero in Q4 2022 as performance obligations completed June 2022; total milestones and royalties potential $855M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

Protagonist Therapeutics, Inc reported the fourth quarter ended December 31, 2022 results: revenue zero.

Period: the fourth quarter ended December 31, 2022
Revenue: zero
Result: reported results

Exact text from the filing

License and Collaboration Revenue : License and collaboration revenue for the fourth quarter and full year 2022 were zero and $26.6 million, respectively, as compared to $8.6 million and $27.4 million for the same periods of 2021.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

Protagonist Therapeutics, Inc reported the full year ended December 31, 2022 results: revenue $26.6 million.

Period: the full year ended December 31, 2022
Revenue: $26.6 million
Result: reported results

Exact text from the filing

License and Collaboration Revenue : License and collaboration revenue for the fourth quarter and full year 2022 were zero and $26.6 million, respectively, as compared to $8.6 million and $27.4 million for the same periods of 2021.

View on SEC.gov

Browse all earnings releases →

Protagonist Therapeutics, Inc filing history →

Source: SEC EDGAR

accession 0001104659-23-032774

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.